Govan V A, Christensen N D, Berkower C, Jacobs W R, Williamson A-L
Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Medical School, Observatory 7925, and National Health Laboratory Service, Groote Schuur Hospital, Observatory, Cape Town, South Africa.
Vaccine. 2006 Mar 15;24(12):2087-93. doi: 10.1016/j.vaccine.2005.11.029. Epub 2005 Nov 28.
Recombinant Bacille Calmette-Guerin (rBCG) could potentially be the vaccine vehicle of choice to deliver foreign antigens from multiple pathogens. In this study we have used the cottontail rabbit papillomavirus (CRPV) rabbit model to provide a "proof of concept" that immunisation with rBCG expressing the CRPV major capsid protein, L1 (rBCG/CRPVL1), will protect outbred New Zealand White rabbits against CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (10(7) cfu/ml) were protected 5 weeks post-CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (10(5) cfu/ml) had papillomas, which were smaller and took longer to appear than the control rabbits. None of the negative control rabbits vaccinated with rBCG expressing an irrelevant gene or PBS were protected from CRPV challenge. Sera from rabbits immunised with rBCG/CRPVL1 (10(7) cfu/ml) were able to neutralise 54.5% of CRPV at serum dilutions of 1:200. These results provide evidence that BCG could potentially be used as a vaccine delivery vehicle for human papillomavirus proteins as a possible prophylactic vaccine.
重组卡介苗（rBCG）有可能成为递送多种病原体外源抗原的首选疫苗载体。在本研究中，我们利用棉尾兔乳头瘤病毒（CRPV）兔模型来提供“概念验证”，即接种表达CRPV主要衣壳蛋白L1的rBCG（rBCG/CRPVL1）可保护远交新西兰白兔免受CRPV攻击。用rBCG/CRPVL1（10⁷cfu/ml）免疫的兔子在CRPV攻击后5周受到保护。用rBCG/CRPVL1（10⁵cfu/ml）免疫的兔子出现了乳头瘤，其比对照兔子的乳头瘤更小且出现时间更晚。接种表达无关基因的rBCG或PBS的阴性对照兔子均未免受CRPV攻击。用rBCG/CRPVL1（10⁷cfu/ml）免疫的兔子的血清在1:200血清稀释度下能够中和54.5%的CRPV。这些结果提供了证据，表明卡介苗有可能作为人乳头瘤病毒蛋白的疫苗递送载体，作为一种可能的预防性疫苗。
